Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJingxin Li, Tao Zhu, Shipo Wu et al.|The Lancet Respiratory Medicine|2022Cited by 172
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Fengcai Zhu, Lihua Hou et al.|Nature Medicine|2022Cited by 163
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Ningshao Xia, Chunlan Zhuang et al.|The Lancet Respiratory Medicine|2022Cited by 140
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Tao Zhu, Hui Zheng et al.|The Lancet Respiratory Medicine|2023Cited by 58
Heterologous prime-boost immunization with CoronaVac and ConvideciaJingxin Li, Fengcai Zhu, Lihua Hou et al.|medRxiv|2021Cited by 33